Encelo Laboratories

Encelo Laboratories, founded in 2020, is pioneering a novel drug delivery and biologics platform centered on non-invasive cell acquisition. Its flagship product, the Cell Catcher, is a consumer-friendly device that captures and preserves viable cells from urine for up to 24 hours, facilitating remote patient monitoring and frequent sampling. The technology targets research and clinical applications in kidney disease, urological cancers, drug screening, and stem cell generation by providing a reliable and accessible source of primary cells. As a private, early-stage company, Encelo is positioned to disrupt traditional biopsy and cell collection paradigms, though its success hinges on clinical validation, adoption, and scaling.

The Cell Catcher: a point-of-care device for non-invasive collection, capture, and 24-hour preservation of live cells from urine.

Potential competition includes companies in liquid biopsy (e.g., for bladder cancer detection using urine), providers of specialized sample collection and stabilization tubes, and research labs developing alternative non-invasive cell sources. Encelo's differentiation lies in its integrated, user-friendly device for live cell preservation at the point of collection.